Tumor necrosis factor (TNF) has a critical role in controlling Mycobacterium tuberculosis , as well as nontuberculous mycobacterial infections ( 1,2 ). Although there are several reports of cutaneous mycobacterial infections, particularly M. marinum , in infl ammatory bowel disease (IBD) patients receiving anti-TNF therapy, to our knowledge no case of disseminated Mycobacterium chelonae related to TNF antagonists has been reported.
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A 72-year-old woman with ulcerative colitis was hospitalized with worsening colitis and transferred to our tertiary care center aft er she failed to respond to more than a week of intravenous steroids. Stool cultures were negative , and fl exible sigmoidoscopy confi rmed severely active chronic colitis.
Preparations were made to initiate anti-TNF therapy, and purifi ed-protein derivative (PPD) tuberculin skin test and T-SPOT. TB (interferon-gamma (IFN-γ ) release) were negative. She received an initial dose of 5 mg / kg infl iximab, and over the next several days she experienced signifi cant improvement. One day before discharge, she developed an erythematous rash on the right hand ( Figure 1a ) , raising a concern for medication reaction. Dermatology was consulted and a skin biopsy was obtained.
Twenty-four hours later, the preliminary report of the skin biopsy revealed fl orid acid-fast bacilli (AFB). Th e biopsy showed a dense subcutaneous infl ammatory infi ltrate, consisting of confl uent sheets of neutrophils ( Figure 1b,c ) with abundant karyorrhexis (fragments of nuclear debris from apoptotic cells; Figure 1d ). Th e main diff erential diagnosis for these histopathologic fi ndings is infection and neutrophilic panniculitides such as early erythema nodosum, erythema induratum, or Sweet ' s syndrome ( 3 ). Special stains for organisms (acid-fast and Fite) showed innumerable positive rod-shaped organisms consistent with Mycobacterium species ( Figure 1e ) .
She was also found to have Klebsiella pneumonia bacteremia and Clostridium diffi cile infection, and was started on imipenem, clarithromycin, amikacin , and oral vancomycin. Because she continued to have severe disease, and could no longer receive aggressive immunosuppression owing to multiple concurrent infections, she underwent proctocolectomy and ileostomy. Th irty-four days aft er the initial Letters to the Editor biopsy of her rash, molecular identifi cation of the AFB revealed M. chelonae , and conventional blood cultures, which had been preliminarily positive for AFB, also revealed M. chelonae aft er 28 days. She was continued on antibiotics and has done well aft er her colectomy.
M. chelonae is a highly drug-resistant mycobacterium that is widely distributed in the environment ( 4 ). It most commonly causes cellulitis and abscesses, and it may present as nodules in the dermis and subcutaneous fat, which can clinically mimic erythema nodosum in patients with IBD. Pathology shows a marked infl ammatory infi ltrate within the dermis or subcutaneous tissue, which ranges from neutrophilic to histiocytic and granulomatous ( 5 -8 ) .
Organisms are almost always identifi ed on acid-fast or Fite stains ( 5, 6 ) , and may be numerous as in the present case.
Assessment of TB status is standard before initiating anti-TNF therapy. Conventional PPD testing uses a mixture of more than 100 diff erent mycobacterial peptides and has poor specifi city for M. tuberculosis , as both BCG vaccination and exposure to nontuberculous mycobacteria produce a positive result. Newer IFN-γ release assays have improved specifi city compared with PPD ( 9 ) . In this assay, peripheral monocytes from patients are cultured with TB antigens in plates coated with anti-IFN-γ antibodies. M. tuberculosis-specifi c T cells, if present, release IFN-γ , which is captured by the plate-bound antibodies, and spots are visualized by enzymelinked immunosorbent assay ( 10 ) . Current IFN-γ release assays use the ESAT-6, CFP-10, and TB7.7 peptides, which are expressed by M. tuberculosis but are absent from BCG vaccine strains and most atypical mycobacteria ( 10, 11 ) . Th is assay therefore does not provide information about past or current nontuberculous mycobacterial infections. A high degree of clinical vigilance for atypical mycobacteria becomes increasingly important as we more precisely target specifi c aspects of innate and adaptive immunity in the treatment of IBD.
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